+91 - 830 - 3146878
Cancer is uncontrolled growth of cells. It can affect any part of the body. The purpose of this presentation study was to evaluate the efficacy of LAS 02 in cervical cancer patients. Total 69 female sex patients were admitted in three citys (Lucknow, Noida and Delhi ) of Lavanya Hospital & Research Centre. 25 to 65 years age ranges were these patients. These patients were only suffering from cervical cancer not from any organic diseases. After obtaining prior consent form, venous blood samples was collected from the subjects before and after treatment with herbomineral drug LAS02 and measured the hematological and biochemical examinations along with ovary cancer biomarker and tumor size.
The results revealed that a statistically (p<0.001) significant reduction of tumor size (mm) and CA125 biomarkers along with significant (p<0.01) decreased ESR levels in patients after treatment with LAS 02 more than one month as compared with before treatment. A significant reduction of hepatic enzymes (SGOT, SGPT, ALP and LDH ) in patients after treatment with drug. These findings suggested that LAS02 is most effective medicine for cure of cervical cancer diseases.
The study was conducted after getting ethical clearance from Institutional human ethic committee. Total 69 cervical cancer patients with age (25-65 years) were enrolled in three city of Lavanya Ayurvedic Hospital and Research Centre. These patients were only suffering from cervical cancer not from any organic diseases. After obtaining prior consent form, venous blood samples was collected from the subjects before (pre) and after treatment (post) with herbomineral drug LAS02 under aseptic condition. The drug was given to these patients for two months. After collection of blood sample, serum and plasma were separated by centrifugation at 4000 rpm for 10 min. at room temperature for measurement of hematological, biochemical parameters along with CA 125 biomarker and total tumor size (mm) in pre and post treated patients.
All hematological and biochemistry parameters hemoglobin (Hb), alkaline phosphate (ALP), Serum glutamate oxaloacetate transminase (SGOT), Serum glutamate pyurvate transminase (SGPT) parameters were measured by fully automatic cell counter and clinical chemistry analyzer.
LDH activity was measured by kit according to protocol provided by supplier (Tranasia biomedical). The activity was expressed as an IU/ml.
Levels of serum CA-125 (Fujirebio Diagnostics, Malvern, PA; Catalog #: 400–10, Lot. # 29191), was determined using a quantitative sandwich enzyme immunoassay according to manufacturer protocol
Resulting data were expressed mean ± SD. Percentage parenthesis was observed between pre vs post treatment with LAS02 drug in cervix patients. Newman Kaul post t test was performed for statistical significance between pre vs post treatment . Where *** is ( p<0.0001, highly significant); ** ( p<0.002, significant) and * ( p<0.05, less significant)
The CA 125 biomarkers were examined in mean age group of 46.2 years (n=11) and mean age group of 52 years (n=58) patients. It was found that a statistically significant decreased CA 125 biomarker in both age groups ( P<0.02 , 56.7%;P<0.0001; 73%) after treatment with LAS02 drug as compared to pre treatment. VIEW CHART
ESR level was also found significant (P<0.0001; 46%) decreased in the patients after treatment with LAS02 in com parison to pre treatment. VIEW CHART
It was found that a statistically significant increased (P<0.0001; 14%) hemoglobin level in treated groups after treatment with LAS02 drug as compared to pre treatment. The SGOT, SGPT, ALP and lacatate dehydrogenase (LDH) activity were significant (P<0.0001, 44%, 50%, 48%; P<0.002, 23%) decreased in patient treated group as compared with pre treated group. VIEW CHART
A highly significant (P<0.0001 ) reduction of tumor size in all treated group as compared with pre treated group. VIEW CHART
Based on clinical base data , it is concluded that the drug is most effective for management and cure of cervical cancer in patients
The purpose of this study was to evaluate the acute oral toxicity study of LAS02 in female Sprague Dawley rat model. [...]
The purpose of this study was to evaluate the maximum tolerated dose of LAS02 in Sprague dawley female rat. [...]
The aim of this study was to evaluate the maximum tolerated dose of LAS02 in female Sprague Dawley rat. [...]